Trial Profile
Daclatasvir plus Sofosbuvir for chronic HCV-infected renal transplant patients – a pilot study of efficacy and safety
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Aug 2022
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 01 Feb 2019 Results evaluating pharmacokinetic profile of combined treatment with Daclatasvir, Sofosbuvir, and GS-331007 in a prospective study of hepatitis C virus (HCV)-positive kidney transplant recipients published in the Therapeutic Drug Monitoring.
- 01 Feb 2019 Status changed from recruiting to completed.
- 03 May 2017 Results assessing PK of combinated daclatasvir (DAC) and sofosbuvir (SOF) therapy, presented at the 2017 American Transplant Congress